"The Devil Wears GP120: Beyond Undetectable - Time to Tackle Inflammation" symposium at Glasgow 2024 was successfully held as a hybrid symposium on Sunday, 10 November 2024 from 12:30 - 13:30 GMT. The symposium was held in the Clyde Auditorium at the Scottish Events Campus (SEC) as part of the HIV Glasgow Congress 2024 in Glasgow, United Kingdom.
As HIV medicine advances, treatment goals for people with HIV have shifted from solely focusing on viral suppression to a more comprehensive approach that includes addressing immune system responses and inflammation. HIV significantly impacts the immune system, leading to clinical challenges, especially for those who experience subdued immune responses and chronic inflammation despite treatment. Even with viral suppression, some highly treated patients may still face poor CD4 responses, influencing their ability to handle infections, vaccinations, and other health determinants, leading to worse outcomes.
Ongoing research is investigating the cellular and clinical effects of the chronic inflammation triggered by HIV. Viral proteins like GP120 play a role in this process, even when the virus is suppressed, and inhibitors like temsavir are being studied for their potential to improve patient outcomes. It's crucial to keep healthcare professionals informed about these developments in HIV treatment to enhance patient care as the population of those living with HIV ages.
There is a need to inform infectious disease healthcare professionals about the cutting-edge research in HIV treatment with respect to the immune system and the inflammatory response in persons living with HIV. The program will address that need and include topics such as why chronic inflammation is seen in individuals with viral suppression, the clinical implications of the chronic inflammatory state, and a deeper dive into the possible interventions. Current state-of-the-art research being conducted based on these concepts will also be presented and discussed.
